Oxytetracycline Hydrochloride and Hydrocortisone Acetate Ophthalmic Suspension
»Oxytetracycline Hydrochloride and Hydrocortisone Acetate Ophthalmic Suspension is a sterile suspension of Oxytetracycline Hydrochloride and Hydrocortisone Acetate in a suitable oil vehicle with one or more suitable suspending agents.It contains the equivalent of not less than 90.0percent and not more than 115.0percent of the labeled amount of oxytetracycline (C22H24N2O9)and not less than 90.0percent and not more than 110.0percent of the labeled amount of hydrocortisone acetate (C23H32O6).
Packaging and storage— Preserve in tight,light-resistant containers.The containers are sealed and tamper-proof so that sterility is assured at time of first use.
Sterility á71ñ It meets the requirements when tested as directed for Direct Inoculation of the Culture Mediumunder Test for Sterility of the Product to be Examined using 0.25mLof specimen.
Water,Method Iá921ñ: not more than 1.0%,60mLof a mixture of methanol and chloroform (2:1)being used instead of methanol in the titration vessel.
Assay for oxytetracycline— Transfer an accurately measured volume of Ophthalmic Suspension to a separator,add 50mLof ether,and shake.Add 25mLof 0.1Nhydrochloric acid,shake,and allow to separate.Collect the acid layer,and repeat the extraction with three additional 25-mLportions of 0.1Nhydrochloric acid.Combine the acid extracts in a 200-mLvolumetric flask,dilute with 0.1Nhydrochloric acid to volume,and mix.Proceed as directed for oxytetracycline under Antibiotics—Microbial Assays á81ñ,using an accurately measured volume of this solution diluted quantitatively and stepwise with water to obtain a Test Dilutionhaving a concentration assumed to be equal to the median dose level of the Standard.
Assay for hydrocortisone acetate—
Mobile phase— Prepare a degassed and filtered mixture of water and methanol (50:50).
Standard preparation— Dissolve an accurately weighed quantity of USP Hydrocortisone Acetate RSin a mixture of Mobile phaseand alcohol (80:20)to obtain a solution having a known concentration of about 0.06mg per mL.
Assay preparation— Transfer an accurately measured volume of Ophthalmic Suspension,equivalent to about 30mg of hydrocortisone acetate,to a separator containing 25mLof pH9.0alkaline borate buffer (see under Buffer Solutionsin the section Reagents,Indicators,and Solutions).Extract with four 25-mLportions of chloroform,filtering each chloroform extract through a thin layer of chloroform-washed anhydrous sodium sulfate into a 250-mLvolumetric flask.Rinse the sodium sulfate with chloroform,collecting the filtrate in the volumetric flask,dilute with chloroform to volume,and mix.Transfer 25.0mLof the resulting solution to a 50-mLconical flask,and evaporate slowly with the aid of mild heat until about 5mLremains.Add about 15mLof alcohol,and evaporate slowly until about 5mLremains.Transfer this solution to a 50-mLvolumetric flask,dilute with a mixture of Mobile phaseand alcohol (80:20)to volume,and mix.
Chromatographic system (see Chromatography á621ñ)—The liquid chromatograph is equipped with a 254-nm detector and a 3.9-mm ×30-cm column that contains packing L1.The flow rate is about 1mLper minute.Chromatograph the Standard preparation,and record the peak responses as directed for Procedure:the column efficiency determined from the analyte peak is not less than 235theoretical plates,the tailing factor for the analyte peak is not more than 1.7,and the relative standard deviation of replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 25µL)of the Standard preparationand the Assay preparationinto the chromatograph,record the chromatograms,and measure the responses for the major peaks.Calculate the quantity,in mg,of C23H32O6in each mLof the Ophthalmic Suspension taken by the formula:
500(C/V)(rU/rS),
in which Cis the concentration,in mg per mL,of USP Hydrocortisone Acetate RSin the Standard preparation;Vis the volume,in mL,of Ophthalmic Suspension taken;and rUand rSare the peak responses obtained from the Assay preparationand the Standard preparation,respectively.
Auxiliary Information— Staff Liaison:William W.Wright,Ph.D.,Scientific Fellow
Expert Committee:(PA7)Pharmaceutical Analysis 7
USP28–NF23Page 1452
Phone Number:1-301-816-8335